People with GA have a part of their immune system that is overactive. Izervay targets and stops a protein called C5. In people with GA, protein C5 signals to other cells to attack certain cells in ...

ACP is not authorized for any indication in any country. ACP is a novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical ...

announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years ...

ACP is approved in the US as Izervay for the treatment of GA secondary to AMD. ACP is a synthetic aptamer that inhibits the complement C5 protein. Overactivity of the complement system and the C5 ...

for Conditional Approval of avacincaptad pegol intravitreal solution (ACP), a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved ...